Gardasil Drug Interactions

Use with Other Vaccines: Results from clinical studies indicate that QUADRIVALENT HUMAN PAPILLOMAVIRUS (TYPES 6, 11, 16, 18) RECOMBINANT VACCINE (GARDASIL) may be administered concomitantly (at a separate injection site) with H-B-VAX II (or insert local trade name) [hepatitis B vaccine (recombinant)], Menactra [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine], Adacel [Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)], and Repevax [Diphtheria, Tetanus, Pertussis (acellular, component) and Poliomyelitis (inactivated) Vaccine, (adsorbed, reduced antigen(s) content)].
Use with Common Medications: In clinical studies for girls and women (aged 16 to 26 years), 11.9%, 9.5%, 6.9%, and 4.3% of individuals used analgesics, anti-inflammatory drugs, antibiotics, and vitamin preparations, respectively. In a clinical study in women (aged 24 to 45 years), 30.6%, 20.2%, 11.6%, and 7.5% of individuals used analgesics, anti-inflammatory drugs, antibiotics, and vitamin preparations, respectively. Conversely in a clinical study in boys and men (aged 16 to 26 years), 10.3%, 7.8%, 6.8%, 3.4% and 2.6% of individuals used analgesics, anti-inflammatory drugs, antibiotics, antihistamines, and vitamin preparations, respectively. The efficacy, immunogenicity, and safety of the vaccine were not impacted by the use of these medications.
Use with Hormonal Contraceptives: In clinical studies, 50.2% of women (aged 16 to 45 years) who received QUADRIVALENT HUMAN PAPILLOMAVIRUS (TYPES 6, 11, 16, 18) RECOMBINANT VACCINE (GARDASIL) used hormonal contraceptives. Use of hormonal contraceptives did not appear to affect the immune responses to QUADRIVALENT HUMAN PAPILLOMAVIRUS (TYPES 6, 11, 16, 18) RECOMBINANT VACCINE (GARDASIL).
Use with Steroids: In clinical studies for girls and women (aged 16 to 26 years), 1.7% (n=158), 0.6% (n=56), and 1.0% (n=89) of individuals used inhaled, topical, and parenteral immunosuppressants, respectively. In a clinical study in women (aged 24 to 45 years), 1.4% (n=27) used corticosteroids for systemic use. In a clinical study in boys and men (aged 16 to 26 years), 1.0% (n=21) used corticosteroids for systemic use. The corticosteroids for all individuals were administered close to the time of administration of a dose of QUADRIVALENT HUMAN PAPILLOMAVIRUS (TYPES 6, 11, 16, 18) RECOMBINANT VACCINE (GARDASIL). These medicines did not appear to affect the immune responses to QUADRIVALENT HUMAN PAPILLOMAVIRUS (TYPES 6, 11, 16, 18) RECOMBINANT VACCINE (GARDASIL). Very few individuals in the clinical studies were taking steroids, and the amount of immunosuppression is presumed to have been low.
Use with Systemic Immunosuppressive Medications: There are no data on the concomitant use of potent immunosuppressants with QUADRIVALENT HUMAN PAPILLOMAVIRUS (TYPES 6, 11, 16, 18) RECOMBINANT VACCINE (GARDASIL). Individuals receiving therapy with immunosuppressive agents (systemic doses of corticosteroids, antimetabolites, alkylating agents, cytotoxic agents) may not respond optimally to active immunization (see Precautions).